UEEC - United Health Products, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.2800
-0.0215 (-1.65%)
As of 2:47PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.3015
Open1.2900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.2500 - 1.3000
52 Week Range0.5500 - 2.5500
Volume67,261
Avg. Volume123,603
Market Cap225.773M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateJan 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    United Health Products Issues Progress Report

    United Health Products (UHP) (OTCPK: UEEC) today announced that 2019 was a pivotal year for the company in which it:

  • Business Wire

    United Health Products Completes Safety and Efficacy Animal Study for HemoStyp® Hydrocolloid Product

    United Health Products (UHP) (OTC: UEEC) today announced that it had completed a safety and efficacy animal study for its HemoStyp hydrocolloid product, for which it filed a patent application in August 2019. The hemostatic hydrocolloid product is formed into a gel, foam or spray in order to control bleeding and oozing from a variety of wounds. If the patent is granted and FDA approval is obtained, HemoStyp could then be bundled as a suite of multiple products for surgical and wound care applications. UHP is also working on two other complementary HemoStyp-based products that could potentially be added to its surgical product suite.

  • GlobeNewswire

    United Health Products Reschedules Corporate Update Call

    HENDERSON, Nev., Nov. 06, 2019 -- United Health Products, Inc. (OTC: UEEC) is rescheduling its corporate update conference call conference to Thursday November 7, 2019 at 4:30.

  • GlobeNewswire

    United Health Products to Host Corporate Update Call

    HENDERSON, Nev., Nov. 04, 2019 -- United Health Products, Inc. (OTC: UEEC) will host a corporate update conference call on Thursday, November 7, 2019 at 11:00 am Eastern Time..

  • GlobeNewswire

    HemoStyp® Human Trial Results Journal Article to be Submitted for Peer Review

    HENDERSON, Nev., Oct. 23, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP”), developer, manufacturer and marketer of HemoStyp, an Oxidized Regenerated Cellulose, today.

  • GlobeNewswire

    United Health Products Announces Positive Results from HemoStyp® Human Clinical Trial

    HENDERSON, Nev., Oct. 18, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose.

  • GlobeNewswire

    United Health Products to Move Manufacturing to U.S.

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose gauze, today announced that it will relocate the majority of its manufacturing operations to a United States facility. UHP is recently partnering with an established contract manufacturing company and is leasing “clean room” space at the partner’s state-of-the-art facility in the Baltimore suburb of Westminster, Maryland. The facility is ISO 9001 and 13485 certified, and offers certain engineering and technical services that will help UHP rapidly increase production of existing and new HemoStyp formats, in anticipation of a successful FDA Class III PMA application approval, the potential acquisition of the Company  or a strategic partnership.  Once fully operational, the facility will be capable of manufacturing up to 20 million square inches of HemoStyp gauze monthly.

  • GlobeNewswire

    United Health Products Files Defamation Lawsuit Against Short Sellers

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose, today announced it has filed a defamation, trade libel and unlawful and deceptive practices lawsuit against White Diamond Research LLC, Adam Gefvert, Streetsweeper.org, Sonya Colberg and those others who aided and abetted the foregoing defendants’ stock manipulation scheme to injure UHP for illegitimate personal gain, in the Nevada District Court for Clark County. The Complaint alleges that in August 2019 White Diamond Research LLC and Adam Gefvert, Streetsweeper.org, and Sonya Colberg published false and defamatory statements about UHP in “short and distort” schemes to artificially drive down the market price of UHP’s common stock while at the same time having a short position in UHP’s stock, so they could obtain illicit profits on their short sale positions.

  • Globenewswire Test

    United Health Products Announces Submission of Premarket Approval (PMA) Application to the U.S. FDA for the HemoStyp® Device for Use in Surgical Procedures

    HENDERSON, Nev., Oct. 04, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC: UEEC) today announced that it has submitted a Premarket Approval (PMA) application for Class III approval to the FDA for HemoStyp. The PMA program confirms the safety and efficacy of a product. If approved, UHP expects that HemoStyp will be authorized for use in surgical procedures in abdominal, cardiovascular, thoracic and vascular surgeries per UHP’s PMA filed Instructions For Use. HemoStyp’s PMA application falls under SUBCHAPTER H--MEDICAL DEVICES PART 878 -- GENERAL AND PLASTIC SURGERY DEVICES. Subpart E--Surgical Devices Sec. 878.4490 Absorbable hemostatic agent and dressing. An absorbable hemostatic agent or dressing is a device intended to produce hemostasis by accelerating the clotting process of blood. It is absorbable; is intended for internal surgical use; and, is classified as a Class III device.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=878.4490About United Health ProductsUHP develops, manufactures, and markets patented hemostatic gauze for the healthcare and wound care sectors. Its proprietary product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, is designed to absorb exudate/drainage from superficial wounds, and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets. For more on UHP visit: www.unitedhealthproductsinc.comSafe Harbor StatementSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.Company Contact: United Health Products Inc. 877-358-3444IR Contact: Pan Consultants Ltd. Philippe Niemetz   212–344-6464

  • GlobeNewswire

    United Health Products Appoints Dr. Gerard Abate Chief Medical Director

    HENDERSON, Nev., Sept. 06, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for.

  • GlobeNewswire

    Recent Publicity About United Health Products

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose, today announced that over the past 2 ½ weeks articles have been published about UHP, without UHP’s review or participation, by persons unrelated to UHP who disclosed in those articles that they were in a short position in UHP stock. The Company is examining with counsel and advisors those publications and assessing the matter. UHP discloses information about our Company in various ways: Filing reports with the Securities Exchange Commission, disseminating press releases and holding announced shareholder/investor calls from time-to-time.

  • GlobeNewswire

    Corrected News Release - United Health Products Announces Completion of Human Trial Study

    HENDERSON, Nev., Aug. 28, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose.

  • GlobeNewswire

    United Health Products Announces Completion of Human Trial Study

    HENDERSON, Nev., Aug. 28, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose.

  • GlobeNewswire

    United Health Products Announces Completion of Pathology and Study of Preclinical Bone Application of HemoStyp®

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it had received the pathology results of a preclinical animal study to assess the effect of HemoStyp on the bone. This study and indication is independent of the current PMA application and will potentially allow UHP acess to a new and significant market opportunity. UHP believes that these preliminary results demonstrate the safe application of HemoStyp in orthopedic procedures.

  • GlobeNewswire

    United Health Products Files New Patent Application Method of Forming and Using a Hemostatic Hydrocolloid

    United Health Products, Inc. (UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, today announced that it has filed a patent application covering methods of forming and using a hemostatic material, and more specifically, methods of forming and using a hemostatic hydrocolloid that is formed into a gel, foam or spray used to control bleeding and oozing from a variety of wounds. Upon approval of the new patent, this will allow for the HemoStyp hydrocolloid to act as a conduit to transfer other properties associated with the treatment of wounds within the hydrocolloid. “This enables HemoStyp to be bundled as a suite of multiple products for surgical and wound care applications,” said Louis Schiliro, COO, UHP.

  • GlobeNewswire

    United Health Products Announces the Completion of Human Trial Surgery Enrollment

    HENDERSON, Nev., Aug. 05, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Issues Shareholder Update

    It expects to complete enrollment and all surgical procedures for its human clinical trial on or around mid-July 2019. David W. Ramey DVM has prepared a presentation —How to Use a Hemostatic Gauze Product to Help Control Bleeding in Clinical Settings in the Horse— which will be published in the Journal of Veterinary Emergency and Critical Care.

  • GlobeNewswire

    United Health Products Announces Completion of IQVIA Independent Market Assessment for HemoStyp® in Support of Review of Strategic Alternatives

    HENDERSON, Nev., May 07, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the.

  • GlobeNewswire

    United Health Products Retains IQVIA to Conduct U.S. Market Commercialization Study of HemoStyp® in Support of Société Générale’s Strategic Review

    HENDERSON, Nev., April 24, 2019 -- United Health Products, Inc. (OTC: UEEC), (“UHP” or “the company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for.

  • GlobeNewswire

    United Health Products Announces 2018 Results

    United Health Products, Inc. (UEEC) (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today filed its Form 10-K for the year ended December 31, 2018. Douglas K. Beplate, President and CEO said, “2018 was the most important year to date in our company’s development: we shifted our corporate focus to achieving FDA Class III approval for our products in human surgical applications.  We believe that gaining access to this $3.4 billion segment of the hemostatic gauze market is the best path to creating value for our shareholders and so we have devoted our resources fully to that objective. In February 2018, the Company completed and submitted to the U.S. Food and Drug Administration (“FDA”) all materials relevant for the pre-market approval (“PMA”) for HemoStyp under the FDA’s new and innovative CtQ Pilot-Program as a Class III application for internal surgical procedures.